Fruquintinib
- Generic Name
- Fruquintinib
- Brand Names
- Fruzaqla
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19N3O5
- CAS Number
- 1194506-26-7
- Unique Ingredient Identifier
- 49DXG3M5ZW
- Background
Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.
- Indication
本品单药适用于既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗，以及既往接受过或不适合接受抗血管内皮生长因子（VEGF）治疗、抗表皮生长因子受体（EGFR）治疗（RAS野生型）的转移性结直肠癌（mCRC）患者。
Neoadjuvant Treatment of Fruquintinib Combined With Concurrent Chemoradiotherapy for LARC
- Conditions
- Rectal Cancer
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Henan Provincial People's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05575635
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
- Conditions
- Advanced Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 265
- Registration Number
- NCT05522231
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
🇨🇳Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2022-08-22
- Target Recruit Count
- 102
- Registration Number
- NCT05511051
- Locations
- 🇨🇳
People's Hospital of Inner Mongolia, Hohhot, China
🇨🇳Dalian Medial University Affiliated Second Hospital, Dalian, China
🇨🇳Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy
- Conditions
- Colorectal Cancer Stage IVColorectal Cancer
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 116
- Registration Number
- NCT05451719
Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Weijian Guo
- Target Recruit Count
- 134
- Registration Number
- NCT05447715
- Locations
- 🇨🇳
Fudan University Cancer Hospital, ShangHai, Shanghai, China
Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 39
- Registration Number
- NCT05435313
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy
- Conditions
- Advanced Colorectal CarcinomaLiver Metastasis Colon Cancer
- Interventions
- Procedure: Hepatic Arterial Infusion Chemotherapy
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 27
- Registration Number
- NCT05406206
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Fruquintinib DDI Study With P-gp and BCRP Substrates
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 32
- Registration Number
- NCT05368805
- Locations
- 🇺🇸
PPD Development, Austin, Texas, United States
Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2022-03-31
- Target Recruit Count
- 71
- Registration Number
- NCT05292417
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 32
- Registration Number
- NCT05257122
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.